Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403059 | 0.82 | SLC22A6 (0.36) | KDM4EATMSLC22A6GPR84MAPT | |
| SCHEMBL977494 | 0.82 | SLC22A6 (0.36) | KDM4EATMSLC22A6GPR84MAPT | |
| SCHEMBL28538742 | 0.77 | KDM4E (0.43) | KDM4EATMKDM1ASLC22A6 | |
| SCHEMBL1194994 | 0.77 | KDM4E (0.43) | KDM4EATMKDM1ASLC22A6 | |
| SCHEMBL15482735 | 0.77 | KDM4E (0.43) | KDM4EATMKDM1ANR4A1NR4A2 | |
| SCHEMBL27474236 | 0.75 | ALDH1A1 (0.48) | KDM4EATMKDM1A | |
| SCHEMBL291583 | 0.75 | ALDH1A1 (0.48) | KDM4EATMKDM1A | |
| SCHEMBL291582 | 0.75 | ALDH1A1 (0.48) | KDM4EATMKDM1A | |
| SCHEMBL1786508 | 0.71 | ALDH1A1 (0.39) | — | |
| SCHEMBL1786510 | 0.71 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | MIYANO MASAYUKI | 2011-06-09 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7816401-B2 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | KANADA REGINA MIKIE | 2010-08-12 | — | — | US | disclosed |
| EP-2145886-A1 | TWELVE-MEMBERED CYCLOMACROLACTAM DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1935893-A1 | TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | Eisai R&D Management Co., Ltd. (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | HDAC11, HDAC1, HDAC3 | KDM4E 2234/4885ATM 2958/4885KDM1A 1430/4885 |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | CYP8B1, PLA2G2D, HPD | KDM4E 2189/4885ATM 4541/4885KDM1A 3619/4885 |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC1 | KDM4E 2305/4885ATM 3176/4885KDM1A 1617/4885 |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | TPD52L2, CYP8B1, HPD | KDM4E 2440/4885ATM 2684/4885KDM1A 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.